Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Inventory (2016 - 2025)

Historic Inventory for CorMedix (CRMD) over the last 10 years, with Q3 2025 value amounting to $28.9 million.

  • CorMedix's Inventory rose 33486.94% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 33486.94%. This contributed to the annual value of $7.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that CorMedix reported Inventory of $28.9 million as of Q3 2025, which was up 33486.94% from $9.6 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Inventory peaked at $28.9 million during Q3 2025, and registered a low of $269.0 during Q3 2022.
  • Moreover, its 4-year median value for Inventory was $1.2 million (2021), whereas its average is $4.8 million.
  • In the last 5 years, CorMedix's Inventory tumbled by 9945.01% in 2022 and then surged by 33486.94% in 2025.
  • Quarter analysis of 4 years shows CorMedix's Inventory stood at $3008.0 in 2021, then crashed by 91.06% to $269.0 in 2022, then soared by 2825005.95% to $7.6 million in 2024, then skyrocketed by 280.51% to $28.9 million in 2025.
  • Its Inventory was $28.9 million in Q3 2025, compared to $9.6 million in Q2 2025 and $7.5 million in Q1 2025.